Taiwanese Journal of Obstetrics and Gynecology
Volume 50, Issue 1 , Pages 79-84 , March 2011

Three-cycle fentanyl patch system contributes to stable control of plasma fentanyl concentration in gynecologic cancer pain patients

  • Chiharu Kanamori

      Affiliations

    • Department of Obstetrics and Gynecology, Kansai Medical University, Moriguchi, Osaka, Japan
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, Kansai Medical University, Humizonocho, Moriguchi, Osaka 570-8506, Japan.
    • ,
  • Takanobu Kanamori

      Affiliations

    • Department of Obstetrics and Gynecology, Kayashima Ikuno Hospital, Kadoma, Osaka, Japan
    • Kanamori Ladies Clinic, Joyo, Kyoto, Japan
    • ,
  • Yoshiaki Tanaka

      Affiliations

    • Department of Obstetrics and Gynecology, Kayashima Ikuno Hospital, Kadoma, Osaka, Japan
    • ,
  • Hideharu Kanzaki

      Affiliations

    • Department of Obstetrics and Gynecology, Kansai Medical University, Moriguchi, Osaka, Japan

,Accepted 7 September 2009.

References 

  1. Mystakidou K, Tsilika E, Parpa E, Kouloulias V, Kouvaris I, Georgaki S, et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer. 2003;107:486–492
  2. Sloan PA, Moulin DE, Hays H. A clinical evaluation of the transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage. 1988;16:102–111
  3. Calis KA, Kohler DR, Corso DM. Trandermally administrated fentanyl for pain management. Clin Pharm. 1922;11:22–36
  4. Konishi H, Ishihara C, Chiba M, Endo Y, Yamaji A. Pain recurrence on the third day after application of a transdermal fentanyl patch. Pharm World Sci. 2005;27:353
  5. Kanamori C, Kanamori T, Hayashi M, Yorioka H, Kanzaki H. Three-cycle fentanyl patch system significantly improves pain control in gynecologic cancer. J Obstet Gynaecol Res. 2006;32:605–609
  6. Efficacy and safety of Durogesic® in the treatment of chronic cancer pain in routine clinical practice. Janssen Pharmaceutica (Canada), data on file, report number 109759/2: Durogesic® clinical evaluation program; 1995.
  7. Hays H, Gardener-Nix JS. An open clinical evaluation of Durogesic® in the treatment of chronic cancer pain. American Pain Society 14th Annual Meeting; 1995;17–21 [abstract].
  8. Zech DFJ, Grond SUA, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain—a pilot study with 20 terminally ill cancer patients. Pain. 1992;50:293–301
  9. Jeal W, Benfield P. Trandermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53:109–138
  10. Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000;14:111–119
  11. Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52:389–396
  12. Tawfik MO, Bryuzgin V, Kourteva G FEN-INT-20 Study Group. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin. 2004;20:259–267

PII: S1028-4559(11)00007-6

doi: 10.1016/j.tjog.2011.01.006

Taiwanese Journal of Obstetrics and Gynecology
Volume 50, Issue 1 , Pages 79-84 , March 2011

Article Tools

* Image Usage & Resolution